Sera from 113 multiply transfused patients with bleeding disorders of whom 92 (81.4 per cent) were hemophiliacs were tested for such hepatitis‐B virus (HBV) markers as HBsAg, anti‐HBs. anti‐HBc, e‐antigen and anti‐e. For comparison these marker tests were conducted on sera from 398 apparently healthy blood donors, 198 were previously known to be both HBsAg and anti‐HBs negative, 126 were anti‐HBs positive and 74 were HBsAg positive. Among patients with bleeding disorders, overt HBV infections were infrequent (2 per cent) and there was a low prevalence of HBsAg (3.5 per cent), e‐antigen (1 per cent) and anti‐e (0 per cent). However, the prevalence of anti‐HBs (63 per cent) and anti‐HBc (55 per cent) was high. Of the 71 anti‐HBs positive patients with bleeding disorders 54 (76 per cent) were also anti‐HBc positive. The sera of only four patients contained anti‐HBc alone. All but one of the patients with bleeding disorders who were anti‐HBc positive exhibited persistent responses. Anti‐HBc was detected in all the HBsAg positive blood donors and in 113 of 126 (90 per cent) of those who were anti‐HBs positive, but in none who were HBsAg and anti‐HBs negative. The highest titers of anti‐HBc, both among blood donors and patients with bleeding disorders occurred in those who were HBsAg positive. Among patients who were both anti‐HBs and anti‐HBc positive, highest anti‐HBc titers occurred in those aged 31 to 40. Anti‐e was detected in 59 per cent of HBsAg positive and 5 per cent of anti‐HBs positive blood donors, but e‐antigen was detected in none.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.